A Phase 2 clinical trial involving octreotide was updated on October 2, 2026. The study, titled "Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome," is listed under identifier NCT02019706. According to the latest update, the trial's current status is recruiting. The study is designed to evaluate different imaging approaches, including octreotide-based imaging, alongside 68Ga-DOTATATE PET/CT and F-DOPA PET imaging, in patients with ectopic Cushing syndrome. No results have been posted as part of this update. The trial remains in Phase 2 and continues to enroll participants as of the reported date. This update reflects only the recruitment status and does not include outcome data or efficacy findings. Readers interested in octreotide's approved uses and general background can consult the compound overview for additional context.
Octreotide Imaging Trial for Ectopic Cushing Syndrome Still Recruiting
See the full octreotide overview
Source: https://clinicaltrials.gov/study/NCT02019706